7 Analysts Have This To Say About Celldex Therapeutics
Portfolio Pulse from Benzinga Insights
7 analysts have shared their evaluations of Celldex Therapeutics (NASDAQ:CLDX) over the past three months, with a mix of bullish and somewhat bullish ratings. The average 12-month price target is $76.29. The company has shown significant revenue growth but faces challenges with net margins.
August 12, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Celldex Therapeutics has received mixed ratings from 7 analysts, with a majority being bullish. The average 12-month price target is $76.29. The company has shown significant revenue growth but faces challenges with net margins.
The majority of analysts are bullish on CLDX, with a consistent average price target of $76.29. The company's significant revenue growth is a positive indicator, but challenges with net margins may temper short-term gains.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100